Ensuring stability and precision in next-generation mRNA delivery
As lipid nanoparticle (LNP)-based therapeutics continue to redefine the future of medicine, maintaining drug stability from formulation to injection is more critical than ever. The integrity of each nanoparticle—and the container that carries it—directly determines the safety, efficacy, and scalability of mRNA-based treatments.
The latest white paper by Stevanato Group, in collaboration with researchers at the University of Padua (Italy), explores how primary packaging can influence LNP stability and performance. The study provides essential data and testing results that help developers select reliable syringe systems for this rapidly growing therapeutic class.
Evaluating primary containers for LNP-based delivery
The report, “Evaluating Stevanato Group’s primary container portfolio for LNP-based mRNA delivery,” examines how container design, material compatibility, and process control affect the delicate balance between particle integrity and bioactivity.
Readers will gain insights into:
- The evolution of LNP-based therapies and their unique container requirements.
- The data gap in container–drug interaction studies and how it can be addressed.
- Compatibility testing results for Stevanato Group’s prefilled syringe platforms.
- Practical container solutions that preserve LNP stability during storage and administration.
- How to de-risk LNP delivery strategies through validated container systems.
Bridging innovation and reliability
Prefilled syringes are emerging as a leading delivery format for advanced biologics. Yet, the interaction between lipid nanoparticles and syringe materials—such as glass, silicone, and polymer coatings—can significantly influence stability and therapeutic activity.
Stevanato Group’s research underscores how controlled manufacturing, advanced material selection, and precision testing ensure that LNP-based mRNA drugs remain both stable and biologically active up to the point of use.
Download the full white paper
For researchers and developers working in mRNA and nanoparticle delivery, this publication offers a concise yet comprehensive overview of how packaging design can directly impact product performance and regulatory confidence.
Towards safer, smarter biologics
LNP-based therapies are revolutionizing vaccines, oncology, and rare disease treatments. Through innovations in container science, companies like Stevanato Group are helping ensure these life-changing molecules reach patients safely and effectively—without compromising integrity or quality.